We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

News

News

Recipharm and CTC Forms New Collaboration

Both companies will offer a complete set of packages for Phase I studies.
News

ASMS 2014 Overview

We take a look at some of the major new product announcements from ASMS 2014.
News

Waters, Prosolia Exclusive Agreement for DESI Technology for Clinical MS Applications

Prosolia DESI Technology now available on SYNAPT G2 Si and Xevo G2-XS QTof mass spectrometers.
News

BioLineRx Receives Notice of Allowance from the USPTO for the BL-7010 Patent

Results of ongoing Phase 1/2 trial for BL-7010 expected in next few weeks.
News

Finding Could Revolutionize Drug Discovery

A study by researchers at IRB Barcelona reveals the existence of information highways that connect and correlate distant sites within a single protein.
News

Ferrer Initiates Second Phase III Clinical Study for Ozenoxacin

Ozenoxacin, a novel bactericidal non-fluorinated quinolone that successfully completed a first phase III clinical trial in adult and paediatric patients with impetigo, is available from Ferrer for licensing and commercialization.
News

TxCell Granted Certificate of GMP Compliance for Cell Therapy Manufacturing Facility

Confirmation of quality of TxCell’s manufacturing platform by ANSM enables regulatory submissions for Ovasave® phase IIb clinical study.
News

Advanced Cell Culture Techniques for Cancer Drug Discovery

This review focuses on the culturing of cell lines representative of solid cancers in advanced cell culture conditions.
News

Parker Extends Clean Room Cell Capabilities at its Prädifa Plant in The Czech Republic

Ultra-modern clean room manufacturing cell for elastomer and plastic components is specifically designed for meeting the demands of the medical and pharmaceutical industries.
News

X-Chem, Pfizer Enter Multi-Target Collaboration

Partnership is focused on the potential development of several programs for the treatment of inflammatory and orphan diseases.
Advertisement